Valneva SE (VALN) Cash & Current Investments (2020 - 2026)
Valneva SE's (VALN) quarterly Cash & Current Investments came in at $123.2 million in Q1 2026, down 30.37% year-on-year from $177.0 million in Q1 2025, and down 3.45% quarter-over-quarter from $127.6 million in Q4 2025.
Valneva SE (VALN) Cash & Current Investments (2020 - 2026) Analysis & Trends
Valneva SE has disclosed Cash & Current Investments across 7 years of filings, most recently posting $123.2 million for Q1 2026.
- Cash & Current Investments for Q1 2026 came in at $123.2 million, down 30.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $123.2 million (down 30.37% YoY), and the FY2025 annual result was $127.6 million, down 29.55% from the prior year.
- Cash & Current Investments came in at $123.2 million for Q1 2026 at Valneva SE, down from $127.6 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $389.0 million in Q1 2022 to a low of $312011.7 in Q2 2023.
- The 5-year median for Cash & Current Investments is $181.2 million (2024), against an average of $207.3 million.
- Across the five-year window, Cash & Current Investments plunged 99.91% in 2023 and jumped 45256.32% in 2024, its largest moves.
- Valneva SE's Cash & Current Investments stood at $292.3 million in 2022, then sank by 53.6% to $135.7 million in 2023, then jumped by 33.56% to $181.2 million in 2024, then declined by 29.55% to $127.6 million in 2025, then decreased by 3.45% to $123.2 million in 2026.
- The last three Cash & Current Investments figures came in at $123.2 million (Q1 2026), $127.6 million (Q4 2025), and $167.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 2.77 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 18.44 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | 123.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 123.24 Mn |
| Dec 31, 2025 | 127.64 Mn |
| Sep 30, 2025 | 167.76 Mn |
| Jun 30, 2025 | 184.08 Mn |
| Mar 31, 2025 | 177.00 Mn |
| Dec 31, 2024 | 181.19 Mn |
| Sep 30, 2024 | 171.65 Mn |
| Jun 30, 2024 | 141.52 Mn |
| Mar 31, 2024 | 191.89 Mn |
| Dec 31, 2023 | 135.65 Mn |
| Sep 30, 2023 | 311.92 Mn |
| Jun 30, 2023 | 312,011.68 |
| Mar 31, 2023 | 307.55 Mn |
| Dec 31, 2022 | 292.33 Mn |
| Sep 30, 2022 | 263.20 Mn |
| Jun 30, 2022 | 358.77 Mn |
| Mar 31, 2022 | 389.05 Mn |
| Dec 31, 2021 | 396.60 Mn |
| Sep 30, 2021 | 241.04 Mn |
| Jun 30, 2021 | 397.13 Mn |